Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study-Reference-Cited by-同舟云学术

Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study

Published:1998-01-23 Issue:5350 Volume:279 Page:563-566
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Chan June M.¹²³⁴⁵,Stampfer Meir J.¹²³⁴⁵,Giovannucci Edward¹²³⁴⁵,Gann Peter H.¹²³⁴⁵,Ma Jing¹²³⁴⁵,Wilkinson Peter¹²³⁴⁵,Hennekens Charles H.¹²³⁴⁵,Pollak Michael¹²³⁴⁵

Affiliation:

1. J. M. Chan and M. J. Stampfer, Department of Epidemiology, Harvard School of Public Health, 677 Huntington Avenue, Boston, MA 02115, USA.

2. E. Giovannucci and J. Ma, Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.

3. P. H. Gann, Department of Preventive Medicine, Northwestern University Medical School, Chicago, IL 60611, USA.

4. P. Wilkinson and M. Pollak, Cancer Prevention Research Unit, Departments of Medicine and Oncology, Lady Davis Research Institute of the Jewish General Hospital and McGill University, Montreal, Canada H3T1E2.

5. C. H. Hennekens, Division of Preventive Medicine, Department of Medicine and Department of Ambulatory Care and Prevention, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.

Abstract

Insulin-like growth factor–I (IGF-I) is a mitogen for prostate epithelial cells. To investigate associations between plasma IGF levels and prostate cancer risk, a nested case-control study within the Physicians' Health Study was conducted on prospectively collected plasma from 152 cases and 152 controls. A strong positive association was observed between IGF-I levels and prostate cancer risk. Men in the highest quartile of IGF-I levels had a relative risk of 4.3 (95 percent confidence interval 1.8 to 10.6) compared with men in the lowest quartile. This association was independent of baseline prostate-specific antigen levels. Identification of plasma IGF-I as a predictor of prostate cancer risk may have implications for risk reduction and treatment.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference35 articles.

1. Cohen S. M., Ellwein L. B., Science 249, 1007 (1990).

2. P. Cohen D. M. Peehl R. G. Rosenfeld Hormone Metab. Res. 26 81 (1994).

3. Cohen P., Peehl D. M., Lamson G., Rosenfeld R. G., J. Clin. Endocrinol. Metab. 73, 401 (1991).

4. Rajah R., Valentinis B., Cohen P., J. Biol. Chem. 272, 12181 (1997).

5. Jones J. I., Clemmons D. R., Endocr. Rev. 16, 3 (1995).

Cited by 1710 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Simultaneous noninvasive ultrasensitive detection of prostate specific antigen and lncRNA PCA3 using multiplexed dual optical microfibers with strong plasmonic nanointerfaces;Biosensors and Bioelectronics;2024-11

2. Effects of natural extract interventions in prostate cancer: A systematic review and network meta-analysis;Phytomedicine;2024-07

3. Unraveling the link between cardiorespiratory fitness and cancer: a state-of-the-art review;GeroScience;2024-06-03

4. Insulin-like growth factor family and prostate cancer: new insights and emerging opportunities;Frontiers in Endocrinology;2024-05-30

5. The Influence of Exercise on Cancer Risk, the Tumor Microenvironment and the Treatment of Cancer;Sports Medicine;2024-04-30